Chemical risk in hospital settings: Overview on monitoring strategies and international regulatory aspects by Charlier, Bruno et al.
                             Journal of Public Health Research 2021; volume 10:1993
Chemical risk in hospital settings: Overview on monitoring strategies 
and international regulatory aspects
Bruno Charlier,1,2 Albino Coglianese,1 Federica De Rosa,2 Francesco De Caro,1,2
Ornella Piazza,1,2 Oriana Motta,1,2 Anna Borrelli,2 Mario Capunzo,1,2 Amelia Filippelli,1,2
Viviana Izzo1,2
1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi
(SA); 2University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
Abstract
Chemical risk in hospital settings is a growing concern that
health professionals and supervisory authorities must deal with
daily. Exposure to chemical risk is quite different depending on
the hospital department involved and might origin from multiple
sources, such as the use of sterilizing agents, disinfectants, deter-
gents, solvents, heavy metals, dangerous drugs, and anesthetic
gases. Improving prevention procedures and constantly monitor-
ing the presence and level of potentially toxic substances, both in
workers (biological monitoring) and in working environments
(environmental monitoring), might significantly reduce the risk of
exposure and contaminations. The purpose of this article is to pre-
sent an overview on this subject, which includes the current inter-
national regulations, the chemical pollutants to which medical and
paramedical personnel are mainly exposed, and the strategies
developed to improve safety conditions for all healthcare workers.
Introduction
Occupational exposure of healthcare workers to hazardous
chemicals in hospital settings may negatively affect health and
quality of life, and greatly differs depending on the type of clinical
unit and specific job involved.1,2 Chemical exposure in hospital
environments may occur as acute intoxication or be the result of
chronic and time-extended exposure of workers to low doses of
contaminants. It can lead to damage to the nervous, hematopoietic,
or reproductive systems,3 and a potential relationship with neo-
plastic pathologies has been recently underpinned.4
In recent years, increasing attention has been focused on
chemical risk prevention, which includes strategies aimed at pro-
tecting operators from both accidental and chronical exposure.
Biological monitoring (BM) of workers and environmental moni-
toring (EM) of working areas are among the most effective actions
that can effectively improve chemical risk management. Aim of
this article is to provide an overview of the most common chemi-
cal pollutants to which medical and paramedical staff can be pro-
fessionally exposed to, and the different strategies that can be used
to improve chemical risk management.
International regulations 
The European Agency for Safety and Health at Work (EU-
OSHA) was established in the European Union in 1994, with the
aim of improving European workplaces safety, productivity and
health.5 An important milestone in chemical risk management in
workplaces was set by European Union regulation n. 1907/2006,
concerning the Registration, Evaluation, Authorization and
restriction of CHemical products (REACH).6 This latter deals with
the production and use of chemicals and their potential impacts on
human health and environment. The REACH is also considered as
a model in non-European countries such as South Korea. The Act
on Registration, Evaluation, Authorization and restriction of
CHemicals, established in 2015 and named K-REACH, is the
Korean version of the regulation and aligns with the European
model.7
Preventive measures for workers must refer to the Good
Manufacturing Practice and Good Laboratory Practice.8,9 In these
guidelines, specific suggestions for each class of compounds are
continuously updated, according to novel classifications.
Formaldehyde (FA), as an example, has changed from “suspected
causing cancer” agent to “may cause cancer” on January 2016.10
Italian regulation about safety in workplaces was first
described in Legislative Decree (Lgs. D.) n. 626,11 which follows
the European Union (EU) specific directives. Later, Lgs. D n. 626
was updated by the European reference legislation,12 which pro-
vides general guidelines for the management of workers health
prevention. The analysis of the individual risk factors (physical,
chemical, biological) was described in the already mentioned
REACH and its last update EU Regulation n. 1272/2008 (CLP -
Classification Labeling Packaging).13
In the United States, workers safety is managed by two federal
agencies, the National Institute for Safety and Health (NIOSH),
and the Occupational Safety and Health Administration (OSHA),
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created in accordance with the “Occupational Safety and Health
Act” signed on 29 December 1970.14 OSHA is a regulatory agency
that periodically revises safety and health standards, while NIOSH
was established to help ensure safety and healthy working condi-
tions, especially for what concerns the development of guidelines
for work injuries prevention and related diseases.14,15 In addition,
the Environmental Protection Agency,16 an independent executive
agency of the government of the United States, deals with regula-
tions concerning environment appraisal and protection. EPA,
through the Toxic Substances Control Act (TSCA or TOSCA)
issued in 1976, regulates the introduction of new or existing sub-
stances by assessing their chemical risk.17
Environmental and biological monitoring
Occupational exposure to chemical agents should be evaluat-
ed, when possible, by a combined approach involving both envi-
ronmental monitoring (EM) and biological monitoring (BM).18
Environmental monitoring involves the collection of one or
more measurements aimed at identifying and quantifying the pres-
ence, in a specific environment, of potentially harmful pollu-
tants.19,20 EM allows evaluating workers effective exposure to
chemicals and building a risk map by: i) Quantifying exposure to
chemical hazards and evaluating the most advanced methodologies
available to limit their dispersion; ii) Activating emergency control
procedures to contain and mitigate the effects of acute exposure
events; iii) Observing trends of exposure and pollution in
workspaces; iv) Developing safety strategies, based on scientific
data presented in literature.
Quantitative data achieved in the EM should be critically eval-
uated based on the threshold limit values (TLVs) defined for each
pollutant. TLVs are the maximum environmental concentrations of
a compound to which a person can be subjected without adverse
health effects, even in case of a prolonged exposure, and are estab-
lished combining data derived from both epidemiological data
related to the industrial field, and experimental research. However,
it should be underlined that EM and TLVs fail to evaluate the
effective amount of chemicals that permeate through skin, airways
or epithelia, which may be responsible of causing acute or chronic
harmful events in healthcare workers.21 
TLVs for airborne pollutants should consider the dimensional
mass fraction of the compound analyzed, which can be classified
as follows:
• inhalable fraction, collected in any part of the respiratory tract.
• thoracic fraction, collected in the lung and along gas exchange
region.
• respirable fraction, collected in the gas exchange region.
Nowadays, many standardized methods for the measurement
in work settings of toxic chemical agents are available; conversely,
direct methods to evaluate trans-dermic contamination are not
always validated and few standardized procedures for the direct
measurement of dermal exposure have been discussed so far.19
Therefore, when possible, BM is a critical tool to evaluate the
effective absorption of chemical toxic compounds. 
BM can be defined as “a systematic continuous or repetitive
activity for collection of biological samples for analysis of concen-
trations of pollutants, metabolites or specific non-adverse biologi-
cal effect parameters for immediate application, with the objective
to assess exposure and health risk to exposed subjects, comparing
the data observed with the reference level and — if necessary —
leading to corrective actions”.22 In BM, it is possible to analyse
specific biological indicators (BI), which may be considered direct
markers of a real or potential exposure condition.23
BIs can be different according to the biological matrix (urine,
blood, tissues, exhaled air, etc.), organ or tissue in which they orig-
inate and/or accumulate (kidney, liver, nervous system, etc.) and
depending on the specific chemical-physical characteristics
(volatility, hydro-liposolubility, etc.) of the compound/s of interest. 
BIs can be divided into:
• Biological exposure indicators (BEIs)
• Biological response (or effect) indicators (BRIs)
• Biological susceptibility indicators (BSIs).
A BEI can be an exogenous compound, its metabolite, or a prod-
uct of its interaction with a target molecule or cell. BEIs are specific
and often allow comparing values measured in exposed workers
with those of a non-exposed population.23-25 Biological response
indicators rely on the identification and quantification of the biolog-
ical effects that are produced in target tissues, such as chromosomal
aberrations or genetic mutations in somatic cells.23-25
Biological Susceptibility Indicators are biomarkers related to
mechanisms of susceptibility to chemical agents and can be divid-
ed into toxic-kinetic and toxic-dynamic BSI. These indicators
relate on the single organism reaction to an exogenous com-
pound.23-25
Limit values have also been set for BIs. Noteworthy, these val-
ues are generally defined by the Conference of American
Governmental Industrial Hygienists (ACGIH)26 and were initially
established relying on the levels of chemical pollutants present in
the chemical industry.
However, they may not be eligible to assess actual exposure to
lower concentrations used for example in hospital settings, which
can still be harmful for exposed healthcare workers.
Principal pollutants in healthcare facilities
In hospitals and other healthcare facilities, the attention is usu-
ally focused on preventing the biological risk to avoid nosocomial
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Figure 1. Main aspects contributing to environmental and bio-










diseases and accidental infections. However, healthcare workers
are frequently exposed to several types of harmful compounds and,
among them, chemical risk is often underestimated (Figure 1).
Some studies showed a higher frequency of pathologies in hospi-
tals where air quality was judged unsatisfactory compared to those
where air quality standards were respected.27 Nevertheless, the
guarantee of high air quality in hospitals remains a poorly devel-
oped field, both nationally and internationally.
Volatile organic compounds (VOCs) and several other toxic
chemicals (i.e., chemotherapeutic agents, xylenes and anaesthetic
gases as an example) routinely used in healthcare settings and clin-
ical laboratories (Figures 2 and 3) may cause adverse health effects
on exposed people,28 which are different according to inter-indi-
vidual variabilities that may influence pollutant diffusion, neutral-
ization and excretion.20 Airborne pollutants, based on their physi-
cal status and mass, are classified in aeriform and particulate,
which leads to different absorption rates by inhalation, lung reten-
tion times, and alveolar diffusion.19
Formaldehyde
Formaldehyde (FA) is a colourless, acrid-smelling VOC used
for tissue fixation in anatomic pathology laboratories, and can
cross-link with several endogenous organic compounds, such as
proteins and nucleic acids, causing irreversible modifications of
these molecules.29-32 At room temperature FA is gaseous and, con-
sequently, mostly absorbed by inhalation and deposited in the
upper respiratory tract. In addition, as an aqueous solution of for-
malin, skin exposure is also possible. The great reactivity of FA
toward lipids, proteins and nucleic acids is responsible for most
observed toxic effects. Acute or chronic toxic effects are strictly
time- and concentration-dependent: exposure to 0.3-1 ppm (part-
per-million) in the environment cause skin, ocular and upper res-
piratory tract irritation, as well as headache, sleep disorders and
fatigue, while exposure up to 4 ppm is associated to serious respi-
ratory tract irritations. Asthma or nasopharyngeal cancers have
also been reported.33 The Occupational Exposure Limits (OELs)
for formaldehyde are set at 300 part-per billion (ppb; 0.370 mg/m3)
by the ACGIH.26 However, several studies demonstrated that these
limits are often unattended during many procedures, such as autop-
sies.34-36 Bono and co-workers showed that during histological
samples preparation, workers were exposed to air concentrations
of FA above 66 µg/m3, which seemed to be responsible for malon-
dialdehyde-deoxyguanosine adducts (M1-dG), a biomarker of
oxidative stress and lipid peroxidation.36 Costa and co-workers
have screened by comet assay the presence of chromosomal aber-
rations and DNA damage in human peripheral blood lymphocytes
of 84 workers exposed to FA. The data obtained showed a potential
health risk at concentrations higher than 0.38 ppm of FA.37 Starting
December 2009, it has become mandatory to limit FA exposure
levels to protect workers health. As a result, formaldehyde expo-
sure has been further limited setting two-time limit values: the
short-term OEL (15-min reference period) at 0.2 ppm and the 8-h
working day OEL at 0.4 ppm.21
Several BIs have been investigated for the BM of healthcare
workers exposed to FA: complete blood counts, evaluation of sister
chromatid exchange, comet-assay on blood and buccal swab.
While the possibility that inhaled FA may be present in biological
fluids in significant concentrations needs to be further investigated,
quantification of urinary FA at the end of the work shift is so far
the most used test.38-41
Xylene
Xylene, a mixture of three organic isomers of dimethylben-
zene, is a colorless liquid with a sweet and aromatic odor that can
be smelled at 1 ppm, widely used for elimination of paraffin traces
from histological samples before DNA staining or extraction.42
Acute toxicity after exposure to low concentrations of xylene
includes skin, eye, and respiratory tract irritation; however, mas-
sive inhalation can cause central nervous system depression (from
headache to coma and death), pulmonary oedema and respiratory
arrest.43 Long-term exposure can produce anemia, thrombocytope-
nia and leukopenia, cardiac abnormalities with electrocardiogram
modifications, dyspnea, and cyanosis.44 In pregnant women, expo-
sure to xylene increases the probability of spontaneous abortions.
Short-term OELs are set at 100 ppm, and 8-hour OELs at 50
ppm.45
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Figure 2. Chemical structures of common volatile organic com-
pounds (VOCs) used in clinical settings. 
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Anesthetic gases 
The first gaseous anesthetic agent used was nitric oxide in
1844. Subsequently, the use of diethyl ether and FA was approved
for most surgical procedures. In 1950, modern halogenated or flu-
orinated inhalation anesthetic gases were introduced in the clinical
practice. Halothane, a member of this class, is by far the most used
anesthetic gas, along with nitrogen oxide.46 Nowadays, new
inhalation anesthetics such as isoflurane, desflurane, and sevoflu-
rane (Figure 3) are used, alone or in combination with nitrogen
oxide. Halogenated inhalants cause a rapid induction and recovery
of anesthesia and are associated with an early post-operative mobi-
lization because of their low liquid/gas partition coefficient.47
Since 1967, several studies showed that exposure to anesthetic
agents, including halogenated can cause adverse effects on
exposed workers.48-52 Occupational exposure to residual anesthetic
gas concentrations may produce headache, dizziness, lethargy,
fatigue, memory problems, neuro-behavioral changes.53-55 Studies
performed on animal models indicates that chronic exposure to
anesthetic gases can lead to miscarriages and congenital malforma-
tions;47,53,56-59 Popova and co-workers. reported fetal resorption in
rats even at very low concentrations (9 ppm).60
Several bio-monitoring studies have suggested the existence of
a strong relationship between exposure to halogenated anesthetic
gases and the risk of genotoxicity for surgery room staff. It has
been observed that nitric oxide can interfere with vitamin B12 and
irreversibly deactivate methionine synthase in CNS.61,62 Some
studies also report effects of teratogenicity or increase in miscar-
riages in nitric oxide exposed women. A higher prevalence of con-
genital anomalies in the offspring of women professionally
exposed during pregnancy and spontaneous abortions in women
pregnant with exposed men have also been reported.63,64 For these
reasons, it is important to monitor workers exposed to anesthetic
gases by both EM of chemicals in exhaled air and BM of com-
pounds in urine.65-67 Several studies have highlighted a good cor-
relation between measured amounts of unmodified anesthetic
gases in urine and in breathing air; these studies have proposed to
use the same OELs for both BM and EM.68-70 Other authors sug-
gested instead the evaluation of the urinary concentration of anes-
thetic gases metabolites.48,66,71,72
Accepted limits for halogenated substances are 2 ppm when
used alone and 0.5 ppm when in combination with nitrous oxide,
as suggested by NIOSH.15 The ACGIH set the Threshold Limit
Values (TLVs) for nitrous oxide at 50 ppm26 while the Italian
Health Department established the biological exposure limits at 
27 mg/L for urinary nitrous oxide and 3.32 mg/L for urinary isoflu-
rane, equivalent to environmental levels of 50 and 2 ppm, respec-
tively.73 To the best of our knowledge, no TLV are currently pre-
sent for sevoflurane or other halogenated anaesthetic gases.
Anticancer drugs
Anticancer drugs (ADs) are used for the treatment of solid and
hematologic tumors and are classified based on their action mech-
anism; however, most of them do not show specific selectivity
towards cancer cells and thus have an intrinsic cytotoxicity on nor-
mal cells.74 Consequently, the International Agency for Research
on Cancer (IARC) has identified ADs as “potential carcinogens” or
“carcinogens” agent for humans.75
Anticancer drugs toxicity has been known for decades and
include effects such as liver, kidney, gastric, dermatological and
haemopoietic damages.76 Antineoplastic drugs are generally irritat-
ing agent for mucous membranes, and they can cause local toxic
effects (phlebitis, allergies) and systemic effects (anaphylactic
shock and organ toxicity). Cellular necrosis, with lesions that may
cause ulcers variable in severity and extension are also reported.77
According to IARC, it is possible that ADs can cause cancer in
patients treated for non-oncologic pathologies; a well-known
example of this, is the use of immunosuppressive drugs for organ
transplants.78 Furthermore, new tumors formation, unrelated to pri-
mary pathology, has been reported in patients with solid cancers in
treatment with ADs, especially in acute myeloid leukaemia.79
Finally, teratogenic effects on the fetus may occur in ADs exposed
uterus.80
The risks for healthcare workers exposed to ADs have been
known since the 70s, even in case of accidental exposure.81,82
Chronic exposure to small amounts of ADs in healthcare workers
might cause rashes, allergic reactions, or headaches,83 and long-
term effects including genomic instability and increased risk of
reproductive dysfunctions.84-86 Increased AD levels were found in
urine samples of nurses from oncology units compared to other
wards especially during work shifts.82 Anticancer drugs can be
inhaled or adsorbed through skin; cutaneous absorption has been
observed for cyclophosphamide, 5-fluorouracil and methotrexate,
also after the use of Personal Protective Equipment (PPE). This
might be related to the permeability of latex gloves to these
molecules. In addition, cyclophosphamide has a very low vapor
pressure and laminar flow hood cannot retain volatilized
cyclophosphamide molecules that can pass through the large filter
pores.87 Another source of occupational exposure is the domicil-
iary intravenously or subcutaneously administration of chemother-
apeutic agents (a practice that is currently discouraged). In this
case, major risks can arise from air expulsion from the syringe
before drug administration and by drug leaking from connectors or
vials. For these reasons, EM and BM are both required for the cor-
rect management of chemical risk prevention in personnel working
in close contact to antineoplastic drugs, such as laboratories, hos-
pitals and pharmaceutical companies. In EM, AD quantification on
surfaces and objects is carried out using wipes and pad tests.88
Sampling methods in BM
Toxic compounds can be adsorbed by skin contact, inhalation,
and/or ingestion; it mainly depends on the chemical-physical prop-
erties of the molecules and the type of exposure. These character-
istics also influence tissue distribution, as highly water-soluble
pollutants distribute in all body fluids, while lipophilic substances
will likely concentrate in lipid-rich tissues (i.e., the brain). Tissue
characteristics such as composition, pH, permeability and vascu-
larization also influence chemicals absorption in the body. 
Compounds can be eliminated, as intact compounds or their
metabolites, through various pathways, such as breathing, urine,
fecal, and by lactation way. Exogenous compounds undergo
metabolic modifications of their chemical structure, such as oxida-
tion, reduction, hydrolysis or a combination of these, often fol-
lowed by conjugation with an endogenous substrate. Conjugation
is a key-step for exogenous substrates excretion and include reac-
tion with glucuronic acid, amino acids, acetylation, sulphate con-
jugation and methylation. Metabolism and excretion of intact com-
pounds, their metabolites and the ratio between these molecules
are influenced by several inter-individual variabilities such as age,
diet and health status, presence of known polymorphisms that
affect metabolism, body hydration, or time after chemical expo-
sure.89,90 These variables, together with the pharmacokinetic prop-
erties of chemicals, must be taken into consideration during the ini-
tial set-up of an analytical method for the BM of a specific BI. 
Different biological matrixes (e.g., blood, urine, breath) may
be selected based on expected molecule concentration, its kinetics
and the difficulty related to the sample collection (urine and breath










are the less invasive samples to collect).91 Sampling times is also
important and strongly depends on the biological half-life of the
compound of interest and on the time interval during which the
compound has been handled (e.g., sampling before, after or at any
time during the working shift). Sampling of molecules with a short
half-life may give indications on a recent exposure and should be
performed quickly after a potential contact, while monitoring of
long half-life indicators can provide information about a chronic
exposure.90 The analysis of exhaled air (breath test) is an attractive
non-invasive technique for the determination of volatile organic
compounds (VOCs) derived from professional exposure and might
be used for many toxic agents. Although exhaled air is a simpler
matrix compared to urine and blood, the use of breath test in BM
shows some challenges - mainly related for example to the
extremely low concentration of the analyzed compounds - which
hampers its diffusion into routine practice.92
Urine samples are used to measure contaminating chemicals,
metals, and hydrophilic metabolites; however, concentrations may
vary based on urine volume and composition and this may lead to
analytes dilution.89-91 Therefore, normalization of excreted com-
pounds should be performed by using a molecule present at a con-
stant concentration regardless of the urinary volume collected,
such as creatinine. Some volatile chemicals, such as formaldehyde
for example, are eliminated in the kidney by diffusion, which is
driven by the urine/blood distribution coefficient; thus, in this case,
normalization of the concentration value is not required.
Blood is considered as the best biological matrix because the
majority of BIs are present in the blood for a certain amount of
time and data normalization is not required, but venipuncture is an
invasive procedure that must be performed only by trained person-
nel. 
Sampling methods in EM 
Environmental Monitoring activities in workplaces are carried
out to determine the concentration levels of pollutants, according
to their chemical-physical and toxicological characteristics, and to
identify the sources of emission. Environmental monitoring
responds to: i) surveillance activities following confirmed or
potential pollution situations; ii) complaints raised by exposed
workers; iii) surveillance activities to evaluate the effectiveness of
strategies previously adopted; iv) the need for specific information
to facilitate decision-making processes when assessing the expo-
sure of workers with reference to the different residence times in a
given environment; v) the verification of compliance through
guidelines established by competent authorities.
In this framework, a preliminary qualitative evaluation is
required to identify the pollutants or their chemical class. For the
identification and subsequent quantization of environmental pollu-
tants, two approaches are currently available: direct measurement
methods and indirect measurement methods.89
Direct measurement methods use devices and instruments to
quantify gases, vapors or aerosols without user manipulation and
without sending sample to an external laboratory. These devices
allow an immediate evaluation without the need to preserve or
manipulate the sample later. Direct measurement systems general-
ly consist of a sampling system, a detector, an electronic process-
ing system, a display and a memory device. Although they allow
for an immediate evaluation of the concentration pollutant over
time, they suffer of several drawbacks such as measuring range,
detection limit, precision, accuracy, resolution, interference and so
on. Indirect measurements methods involve collecting air samples
in the investigated environment which are then analyzed in labora-
tory. According to monitoring objectives, short-term samplings
(sampling time between a few minutes and several hours) can be
planned, generally carried out with canisters93 or active sampling
on adsorbent cartridges94 or long-term samplings (time sampling
from a few hours to several days), generally performed with diffu-
sive samplers.95
Canisters are stainless steel containers with a variable volume
from 400 ml to 15 L, subjected to an electro-passivation process to
reduce the presence of chemically active polar sites and subse-
quently coated on the internal surface with a thin layer of chemi-
cally silica bonded. The canister, after being cleaned, is placed
under vacuum and is ready for sampling, which can be instanta-
neous or mediated. The instantaneous sampling is performed by
simply opening the valve placed at the closure of the canister,
while the “mediated” one is carried out by applying an orifice cal-
ibrated at the opening of the canister.93 Active sampling, with tubes
containing adsorbent materials, is carried out with appropriate sys-
tems where the air is first drawn into the tube through a sampling
pump, calibrated to the required flow rate. Pollutants react with the
specific substrate causing chromatic variations in a concentration-
dependent manner or can be trapped and, at the end of the sam-
pling, the tubes are stored until desorbed and analyzed in laborato-
ry. Once the sampling phase is complete, the tubes must be closed
with the appropriate caps and stored in glass or metal containers in
refrigerated systems maintained at controlled temperature until
analysis.
Passive devices are used for long-term measurement through a
diffusion air process according to Fick’s laws of diffusion.
Diffusive samplers have been found to be useful and cost-effective
alternatives to conventional pumped samplers. The passive sam-
pler consists of an adsorbent cartridge inserted inside a diffusive
body, whereby analyte molecules diffuse along the concentration
gradient, from the ambient concentration, which corresponds to the
outer part of the sampler, to the effective zero concentration, pre-
sent on the surface of the absorbent within the sampler.95 For both
active and passive method, at the end of the sampling, the pollu-
tants are chemically or thermally desorbed from the support and
transferred for the analytical determination, which can be subse-
quently carried out using various techniques, such as gas chro-
matography, ion chromatography or high-performance liquid chro-
matography (HPLC).95,96
The air quality of operating rooms is usually monitored using
a real-time or an integrated air sampling. In real-time methods, the
concentration of anesthetics is directly measured with a portable
gas-chromatograph equipped with a multiple sampling system. In
integrated air sampling, air is collected on an appropriate adsorbent
tube and analyzed by gas-chromatography in laboratory.15
Methods of analysis
The selection of a suitable analytical method is driven by the
characteristics of each investigated pollutant. For VOCs, the
International Organization for Standardization (ISO) suggests the
use of direct measurement instruments equipped with a flame ion-
ization (FID) or photoionization (PID) detector specific for each
type of pollutant.97 For VOCs analysis, “continuous” automatic
analyzers are widely used; these all-in-one instruments collect the
air sample and perform a real-time analysis. Generally, a specific
device is needed for each analyte. For air sampling, it is important
to define instrument volumetric flow, time of sampling and sam-
pled air volume. However, gas chromatography coupled with mass
spectrometry (GC/MS) remains the gold standard for accurate and
simultaneous quantification of a wide range of VOCs. In this case,
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gaseous substances are collected from the environment or
adsorbed on special supports, eluted with a gaseous mobile phase
and analyzed based on mass/charge ratio for each analyte. For EM
of volatile solvents, such as FA, specific and dedicate equipment is
also available.98
Chromatography has significantly improved both EM and BM.
Compared to classic immunometric or radiolabeling techniques,
chromatography is faster and cheaper. High-performance liquid
chromatography (HPLC) coupled with different types of detectors,
such as Photodiode array, Fluorimeter and other, is available in
almost all healthcare facilities and is employed for the simultane-
ous detection and quantification of many compounds. The use of
liquid chromatography to monitor compounds potentially harmful
to health extends to an ever-increasing number of compounds,
such as solvents,99,100 commonly used drugs101 and cytotoxic
agents.102 Ultra-high-performance liquid chromatography coupled
with tandem mass spectrometry (UHPLC-MS/MS) has a high
selectivity and sensitivity for the simultaneous analysis of several
pollutants and chemicals from complex matrices, such as biologi-
cal fluids, even at very low concentrations.103 The great versatility
and sensitivity of mass spectrometry render this technique suitable
for both BM and EM. UHPLC-MS/MS high selectivity allows for
the simultaneous analysis of a great number of compounds in com-
plex matrices, such as biological fluids, even at very low concen-
trations.104
Inhalation of dust or drug droplets has long been considered
the main route of accidental exposure to toxic agent for hospital
personnel. On the contrary, recent studies indicate skin direct con-
tact as the main route of exposure, especially through the hands
and forearms of nurses and technicians who often wear uniforms
with short sleeves. Exposure can occur also through accidental
ingestion or for hand-to-mouth contamination.105 Therefore, wipe
test is currently the preferred method to check workspace surfaces
and operator gloves.  According to this method, surfaces, gloves or
even the gowns of the operators are rubbed with wipes impregnat-
ed with a solvent. Wipes are then squeezed, and the desorbed sol-
vent is analyzed by previous described chromatographic meth-
ods.88
Conclusions
In recent years, the interest in prevention has been constantly
increasing, diversifying itself from the simple concept of “protec-
tion”, viewed as the whole set of measures and instruments aimed
at protecting from chemical hazard accidental exposure.
Prevention processes involving a routine monitoring of the pres-
ence and level of potentially toxic substances, can reduce the risk
of work injuries derived from chemicals. Furthermore, increasing
attention should be focused on the long-term damage caused by
chronic exposure to contaminants. Safety and health conditions of
all operators operating in health facilities should be the ultimate
goal to look for.
Healthcare workers are frequently exposed to accidental bio-
logical and chemical risks as occasional contamination or pro-
longed exposure. Contaminations are often detected in hospitals,
even when trained staff rigorously carry out all safety procedures
and monitoring practices. For this reason, healthcare facilities need
to routinely monitor and continuously improve risk management
plans and protective equipment, making monitoring simpler, faster,
and less expensive. In addition, the discovery of new-targeted ther-
apies for the treatment of solid and hematologic tumors requires
continuous updates in risk management plans and biohazard risk
prevention that should be directed not only to operators, but also to
all potentially exposed subjects, such as patients’ close relatives or
volunteers. The long-term monitoring and systematic records
could help identifying the risks related to toxic agent exposure.
Therefore, EM and BM in healthcare facilities should not only be
a project plan merely following national and/or internationally reg-
ulations or a solely execution of standard procedures, but a con-
crete tool for an effective protection of all workers involved in
health management.
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